Literature DB >> 21196314

TNF-alpha mediated NF-kappaB activation is constantly extended by transglutaminase 2.

Kang-Seo Park1, Dae-Seok Kim, Chunkyu Ko, Sang-Jin Lee, Seung Hyun Oh, Soo-Youl Kim.   

Abstract

Increased levels of transglutaminase 2 (TGase 2) expression have been reported in many inflammatory diseases, as well as in drug resistant cancer cells. Previous reports have shown that TGase 2 is capable of inducing nuclear factor-kappaB (NF-kappaB) activation via depletion of inhibitor of kappaB (I-kappaB)alpha through polymerization in the absence of I-kappaBalpha kinase activation. This raises the question of whether increased expression of TGase 2 can extend NF-kappaB activation mediated by a canonical activation pathway. In the TGase 2-inducible EcR23/TG cell line, TGase 2 over-expression resulted in sustained activation of NF-kappa B in the presence of TNF-alpha, for up to 24 hrs, while in the absence of TGase 2 induction, NF-kappaB activity was restored to basal levels within 6 hrs of TNF-alpha treatment. In mice injected with an adenovirus vector expressing TGase 2, NF-kappaB was constitutively activated for up to 5 days, whereas Adeno/GFP-injected mice exhibited attenuated activation of NF-kappaB in response to TNF-alpha stress. Thus, the presence of increased levels of TGase 2 may exacerbate NF-kappa B activation in inflammatory states.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21196314     DOI: 10.2741/e249

Source DB:  PubMed          Journal:  Front Biosci (Elite Ed)        ISSN: 1945-0494


  11 in total

1.  Anti-cancer effect of a quinoxaline derivative GK13 as a transglutaminase 2 inhibitor.

Authors:  Seon-Hyeong Lee; Nayeon Kim; Se-Jin Kim; Jaewhan Song; Young-Dae Gong; Soo-Youl Kim
Journal:  J Cancer Res Clin Oncol       Date:  2013-04-21       Impact factor: 4.553

2.  Transglutaminase 2 overexpression in tumor stroma identifies invasive ductal carcinomas of breast at high risk of recurrence.

Authors:  Jasmeet Assi; Gunjan Srivastava; Ajay Matta; Martin C Chang; Paul G Walfish; Ranju Ralhan
Journal:  PLoS One       Date:  2013-09-13       Impact factor: 3.240

3.  Astrocyte-derived tissue transglutaminase interacts with fibronectin: a role in astrocyte adhesion and migration?

Authors:  Miriam E van Strien; John J P Brevé; Silvina Fratantoni; Marco W J Schreurs; John G J M Bol; Cornelis A M Jongenelen; Benjamin Drukarch; Anne-Marie van Dam
Journal:  PLoS One       Date:  2011-09-16       Impact factor: 3.240

4.  Transglutaminase 2 in human diseases.

Authors:  Zsuzsa Szondy; Ilma Korponay-Szabó; Robert Király; Zsolt Sarang; Gregory J Tsay
Journal:  Biomedicine (Taipei)       Date:  2017-08-25

Review 5.  The Role of Tissue Transglutaminase in Cancer Cell Initiation, Survival and Progression.

Authors:  Claudio Tabolacci; Angelo De Martino; Carlo Mischiati; Giordana Feriotto; Simone Beninati
Journal:  Med Sci (Basel)       Date:  2019-01-25

6.  Transglutaminase 2 Up-Regulation Is Associated with Inflammatory Response in PBMC from Healthy Subjects with Hypovitaminosis D.

Authors:  Daniela Caccamo; Nadia Ferlazzo; Monica Currò; Sergio Ricca; Riccardo Ientile
Journal:  Med Sci (Basel)       Date:  2018-11-16

7.  Ultrasound Enhanced Anti-tumor Effect of Temozolomide in Glioblastoma Cells and Glioblastoma Mouse Model.

Authors:  Jie Xue; Yuanyuan Wu; Na Liu
Journal:  Cell Mol Bioeng       Date:  2018-09-06       Impact factor: 2.321

8.  Niche-specific requirement for hyphal wall protein 1 in virulence of Candida albicans.

Authors:  Janet F Staab; Kausik Datta; Peter Rhee
Journal:  PLoS One       Date:  2013-11-08       Impact factor: 3.240

9.  HSP-90 inhibitor ganetespib is synergistic with doxorubicin in small cell lung cancer.

Authors:  C-H Lai; K-S Park; D-H Lee; A T Alberobello; M Raffeld; M Pierobon; E Pin; E F Petricoin Iii; Y Wang; G Giaccone
Journal:  Oncogene       Date:  2013-10-28       Impact factor: 9.867

10.  Secreted Heat Shock Protein 90α Attenuated the Effect of Anticancer Drugs in Small-Cell Lung Cancer Cells Through AKT/GSK3β/β-Catenin Signaling.

Authors:  Yingying Du; Jin Wu; Le Luo
Journal:  Cancer Control       Date:  2018 Jan-Dec       Impact factor: 3.302

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.